177 related articles for article (PubMed ID: 12132671)
1. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
[TBL] [Abstract][Full Text] [Related]
2. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
5. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
6. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
7. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
9. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Lin CJ; Yang JC; Uang YS; Chern HD; Wang TH
Pharmacotherapy; 2003 Jun; 23(6):711-9. PubMed ID: 12820812
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
14. [Tailor-made medicine in Helicobacter pylori eradication therapy].
Aoyama N; Shirasaka D; Miki I
Nihon Rinsho; 2003 Jan; 61(1):129-36. PubMed ID: 12607330
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Rost KL; Roots I
Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 polymorphism and proton pump inhibitors.
Klotz U; Schwab M; Treiber G
Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
[TBL] [Abstract][Full Text] [Related]
18. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
19. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.
Zhou Q; Yamamoto I; Fukuda T; Ohno M; Sumida A; Azuma J
Eur J Clin Pharmacol; 1999 Mar; 55(1):43-7. PubMed ID: 10206083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
